Type 2 DiabetesDiMPLeNCT02195856
Effects of Nitrate on Liver Perfusion and Sugar Control
A study testing Beetroot juice in people with Type 2 Diabetes and Ageing, run by University of Exeter at 2 sites in United Kingdom.
Trial summary
Rationale: Mediterranean style diets and diets rich in green leafy vegetables protect against the risk of developing type 2 diabetes and a wide range of cardiovascular disease. These diets are rich in nitrate. Numerous studies have shown that nitrate from the diet can have a wide range of beneficial effects. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes, Ageing
- What is being tested?
- Beetroot juice
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 31 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- Jul 2014to 20 Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 1. Type 2 Diabetes group; aged between 35 - 75. Able to give informed consent 2. Older adults group; aged between 50 - 75. Not on any regular vasoactive medication and able to give informed consent. 3. Young adults group; aged between18 - 35. Not on any regular vasoactive medication and able to give informed consent.
Who cannot join
- • Antibiotic therapy within the preceding two weeks
- Anyone on GLP-1 analogues or DPP4 inhibitors
- Myocardial infarction or cerebro-vascular event within the preceding three months
- Current smoker (any smoking event in last 3 months)
- Previous brain surgery, cardiac pacemaker.
- Metal fragments in the eye from previous injury
Show all 11Show fewer
- Severe claustrophobia
- Uncontrolled hypertension
- On regular organic nitrates, thiazolidinidiones or nicorandil
- eGFR < 30
- Any other serious medical condition which would interfere with data interpretation or safety.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Exeter Magnetic Resonance Research Centre, St Luke's Campus
Exeter, Devon, EX1 2LU
NIHR Exeter Clinical Research Facility
Exeter, Devon, EX2 5DW
About this study
Official title: The Effect of Dietary Nitrate on Hepatic Perfusion and Incretin Secretion
Rationale:
Mediterranean style diets and diets rich in green leafy vegetables protect against the risk of developing type 2 diabetes and a wide range of cardiovascular disease. These diets are rich in nitrate. Numerous studies have shown that nitrate from the diet can have a wide range of beneficial effects. These include relaxing blood vessels and improving their function. It has been shown that following a meal with added nitrate, blood flow to the stomach increases more than would be expected if the same meal is given without nitrate. This is because when we eat nitrate the body concentrates it and recycles it through the digestive system. As it cycles through it is converted into nitrite and nitric oxide which cause blood vessels to relax. The nitrite and nitric oxide also seem to protect against infection from food sources such as E.coli.
Read more
What we do not know is whether this nitrite and nitric oxide has any effect on the small intestine and the liver. Some nitrite reaches the small intestine and may have the same effect on blood flow there as it does in the stomach. This could be very important because the small intestine releases hormones called incretins which we now know play a very important role in controlling blood sugar every time we eat. These incretin hormones regulate insulin release and the body's sensitivity to insulin. When we eat blood containing the substances we have absorbed from the gut, such as sugars and fats, goes to the liver for processing. The blood then leaves the liver and enters the circulation. This means the blood supply to the liver will have much higher concentrations of nitrite than the blood circulating in the rest of the body. High concentrations of nitrite appear to cause blood vessels to open up. This means more blood vessels in the liver should be opened after a nitrate rich meal. It seems likely that this will help the liver to control blood sugar more effectively.
Purpose To find out if supplementation by inorganic nitrate as found in beetroot or green leafy vegetables increases liver (hepatic) microvascular perfusion and increases incretin secretion.
Plan of investigations:
We will recruit 16 individuals for each of the three groups (Young adults, older adults and individuals with type 2 diabetes). Participants will be recruited from a database of volunteers who have consented to being contacted for research studies which are held by the NIHR Exeter Clinical Research Facility. This is a double blind, placebo controlled crossover design study (nitrate rich beetroot juice vs a placebo, nitrate depleted beetroot juice). Three visits will be required for participants to complete this study.
Visit 1. Screening and consent. The experimenter will explain to the participant what the study is designed to test. If the participant is completely clear on the study and understand what they are agreeing to, they will sign a consent form. In addition a standard medical history and clinical examination will be undertaken by a research nurse and or Anthony Shepherd. A venous blood sample will be taken using standard aseptic procedures. Following consent participants will be assigned a study number. Study numbers will be previously assigned (by a research statistician) to a randomisation order to begin either the beetroot juice or placebo arm of the study first.
Visit 2. Visit 2 will require the participant to fast over night from 10pm. Only water will be admissible from this time. The following morning participants will arrive at the laboratory in a fully hydrated and rested state at ~ 7.30am. This visit will take ~ 5 hours and will require 4 MRI scans. Participants will have the first MRI scan after a short acclimatisation period. Participants will then be provided with a concentrated 140 mL nitrate drink or placebo with a standardised breakfast (2 slices of toast with butter). Three subsequent MRI scans will be required (one per hour for three hours). Venous blood samples taken from cannulas will be sampled, in order to assess glucose, insulin, incretins and nitrate/nitrite prior to each scan. Visit 3. Visit 3 will take place after a minimum washout period of 7 days from Visit 2. Visit 3 will be identical in nature to visit 2; however, it will be with the opposite supplement (either nitrate rich or placebo beetroot juice).
Impact:
Dietary nitrate appears to offer a simple, low cost means of modifying cardiovascular risk. This study will deepen our understanding of the role of the nitrate/nitrite/nitric oxide pathway in normal physiology. By understanding what effect inorganic nitrate from the diet has on hepatic perfusion and other pathways involved in glucose homeostasis this may lead to a range of simple, low cost therapeutic strategies to prevent and treat type 2 diabetes.
Read the detailed description
Hypothesis
Inorganic nitrate from the diet, following conversion to nitrite and nitric oxide via the pathways described above will:
- Increase hepatic microvascular perfusion
- Increase GLP-1 secretion
- Increase pancreatic insulin secretion
- Reduce the area under the curve for glucose post meal
Purpose To find out if inorganic nitrate found in green leafy vegetables protect against the risk of developing type 2 diabetes and cardiovascular disease by increasing hepatic microvascular perfusion and increasing incretin secretion.
Aim The purpose of this study is to see if inorganic nitrate from the diet modulates hepatic perfusion and other pathways involved in post-prandial glucose homeostasis.
MRI Hepatic micro vessel perfusion of the liver and portal vein diameter will be measured by Dr. Jon Fulford at the Peninsula Magnetic Resonance Research Centre, St Luke's Campus. Following initial survey images to obtain anatomical information apparent diffusion coefficients (ADC) are calculated in the posterior right lobe of the liver. Diffusion images are acquired with a single shot echo-planar imaging (EPI) sequence with 15 directions and b values of 200 and 800 s mm-2. Images are acquired during a single breathe-hold at an axial-oblique orientation with a repetition time (TR) of 1500 ms an echo time of 57 ms, an in-plane resolution of 4 x 4 mm and a slice thickness of 10 mm with fat suppression and 3 signal averages.
ADC is given by:
ADC = 1/(b200-b800) Ln (S800/S200) where S800 is the signal with a diffusion b-value of 800 s mm-2 (b800) and S200 is the signal with a diffusion b-value of 200 s mm-2 (b200).
Statistical analysis Statistical analysis will be performed by an experienced and trained researcher and statistical advice will be available from Prof. Angela Shore from within the team and Beverly Shields from the NIHR Exeter Clinical Research Facility. Data will be assessed for normality. Depending on the normality of data the differences between the groups will be assessed by either unpaired t-test or Mann-Whitney test.
Sample Size Sixteen participants would need to be recruited per group in order to detect a 1SD difference between groups data with 80% power and an a of 0.05. Twenty participants would be recruited in order to account for drop outs.
- Conditions
- Type 2 Diabetes, Ageing
- Being tested
- Beetroot juice, Placebo
- Keywords
- Diabetes, Nitrate, Nitrite, Hepatic, MRI, Incretin, Insulin, Glucose
- Medical subject headings
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beetroot juiceDietary supplement
Also called James Whites Drinks Ltd
140mL concentrated Beetroot juice or placebo juice
PlaceboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Diseased condition | Active comparator | Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition. Receives: Dietary Supplement: Beetroot juice |
| Placebo | Placebo comparator | Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hepatic perfusion
Each participant will have 2 visits to the MRI facility. On each visit, they will have 4 scans lasting 12 minutes each.
Measured: 12 minutes
Secondary outcomes (3)
Plasma glucose concentration
Each participant will have 2 visits to the MRI facility. On each visit, they will have 4 scans lasting 12 minutes each. Just before each scan, venous blood samples will be drawn to assess plasma glucose concentration.
Measured: 2 minutes
Plasma insulin concentration
Each participant will have 2 visits to the MRI facility. On each visit, they will have 4 scans lasting 12 minutes each. Just before each scan, venous blood samples will be drawn to assess plasma insulin concentration
Measured: 2 minutes
Plasma incretin concentration
Each participant will have 2 visits to the MRI facility. On each visit, they will have 4 scans lasting 12 minutes each. Just before each scan, venous blood samples will be drawn to assess plasma incretin concentration.
Measured: 2 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2014 (estimated)
- Study startJul 2014
- Primary completion9 Mar 2015
- Study completion20 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Exeter
- Sponsor type
- University, hospital or other
- Collaborators
- Royal Devon and Exeter NHS Foundation Trust
- Responsible party
- Sponsor
- Investigators
- Angela C Shore, PhD, Study chair, University of ExeterAnthony I Shepherd, MSc, Principal investigator, University of Exeter
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02195856
- Sponsor's protocol ID
- CRF163
- Other IDs
- 14/SW/0092
- Acronym
- DiMPLe
- Status last verified
- Mar 2019
- First submitted
- 27 Jun 2014
- Last updated
- 19 Mar 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Dietary Nitrate on Hepatic Perfusion and Incretin Secretion
- ClinicalTrials.gov ID
- NCT02195856
- Acronym / sponsor ID
- DiMPLe / CRF163
- Conditions
- Type 2 Diabetes, Ageing
- Keywords
- Diabetes, Nitrate, Nitrite, Hepatic, MRI, Incretin, Insulin, Glucose
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- University of ExeterUniversity, hospital or other
- Collaborators
- Royal Devon and Exeter NHS Foundation Trust
- Study start
- Jul 2014
- Primary completion
- 9 Mar 2015 (actual)
- Study completion
- 20 Jul 2017 (actual)
- First posted
- 21 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale:
Mediterranean style diets and diets rich in green leafy vegetables protect against the risk of developing type 2 diabetes and a wide range of cardiovascular disease. These diets are rich in nitrate. Numerous studies have shown that nitrate from the diet can have a wide range of beneficial effects. These include relaxing blood vessels and improving their function. It has been shown that following a meal with added nitrate, blood flow to the stomach increases more than would be expected if the same meal is given without nitrate. This is because when we eat nitrate the body concentrates it and recycles it through the digestive system. As it cycles through it is converted into nitrite and nitric oxide which cause blood vessels to relax. The nitrite and nitric oxide also seem to protect against infection from food sources such as E.coli.
What we do not know is whether this nitrite and nitric oxide has any effect on the small intestine and the liver. Some nitrite reaches the small intestine and may have the same effect on blood flow there as it does in the stomach. This could be very important because the small intestine releases hormones called incretins which we now know play a very important role in controlling blood sugar every time we eat. These incretin hormones regulate insulin release and the body's sensitivity to insulin. When we eat blood containing the substances we have absorbed from the gut, such as sugars and fats, goes to the liver for processing. The blood then leaves the liver and enters the circulation. This means the blood supply to the liver will have much higher concentrations of nitrite than the blood circulating in the rest of the body. High concentrations of nitrite appear to cause blood vessels to open up. This means more blood vessels in the liver should be opened after a nitrate rich meal. It seems likely that this will help the liver to control blood sugar more effectively.
Purpose To find out if supplementation by inorganic nitrate as found in beetroot or green leafy vegetables increases liver (hepatic) microvascular perfusion and increases incretin secretion.
Plan of investigations:
We will recruit 16 individuals for each of the three groups (Young adults, older adults and individuals with type 2 diabetes). Participants will be recruited from a database of volunteers who have consented to being contacted for research studies which are held by the NIHR Exeter Clinical Research Facility. This is a double blind, placebo controlled crossover design study (nitrate rich beetroot juice vs a placebo, nitrate depleted beetroot juice). Three visits will be required for participants to complete this study.
Visit 1. Screening and consent. The experimenter will explain to the participant what the study is designed to test. If the participant is completely clear on the study and understand what they are agreeing to, they will sign a consent form. In addition a standard medical history and clinical examination will be undertaken by a research nurse and or Anthony Shepherd. A venous blood sample will be taken using standard aseptic procedures. Following consent participants will be assigned a study number. Study numbers will be previously assigned (by a research statistician) to a randomisation order to begin either the beetroot juice or placebo arm of the study first.
Visit 2. Visit 2 will require the participant to fast over night from 10pm. Only water will be admissible from this time. The following morning participants will arrive at the laboratory in a fully hydrated and rested state at ~ 7.30am. This visit will take ~ 5 hours and will require 4 MRI scans. Participants will have the first MRI scan after a short acclimatisation period. Participants will then be provided with a concentrated 140 mL nitrate drink or placebo with a standardised breakfast (2 slices of toast with butter). Three subsequent MRI scans will be required (one per hour for three hours). Venous blood samples taken from cannulas will be sampled, in order to assess glucose, insulin, incretins and nitrate/nitrite prior to each scan. Visit 3. Visit 3 will take place after a minimum washout period of 7 days from Visit 2. Visit 3 will be identical in nature to visit 2; however, it will be with the opposite supplement (either nitrate rich or placebo beetroot juice).
Impact:
Dietary nitrate appears to offer a simple, low cost means of modifying cardiovascular risk. This study will deepen our understanding of the role of the nitrate/nitrite/nitric oxide pathway in normal physiology. By understanding what effect inorganic nitrate from the diet has on hepatic perfusion and other pathways involved in glucose homeostasis this may lead to a range of simple, low cost therapeutic strategies to prevent and treat type 2 diabetes.
Detailed description
Hypothesis
Inorganic nitrate from the diet, following conversion to nitrite and nitric oxide via the pathways described above will:
- Increase hepatic microvascular perfusion
- Increase GLP-1 secretion
- Increase pancreatic insulin secretion
- Reduce the area under the curve for glucose post meal
Purpose To find out if inorganic nitrate found in green leafy vegetables protect against the risk of developing type 2 diabetes and cardiovascular disease by increasing hepatic microvascular perfusion and increasing incretin secretion.
Aim The purpose of this study is to see if inorganic nitrate from the diet modulates hepatic perfusion and other pathways involved in post-prandial glucose homeostasis.
MRI Hepatic micro vessel perfusion of the liver and portal vein diameter will be measured by Dr. Jon Fulford at the Peninsula Magnetic Resonance Research Centre, St Luke's Campus. Following initial survey images to obtain anatomical information apparent diffusion coefficients (ADC) are calculated in the posterior right lobe of the liver. Diffusion images are acquired with a single shot echo-planar imaging (EPI) sequence with 15 directions and b values of 200 and 800 s mm-2. Images are acquired during a single breathe-hold at an axial-oblique orientation with a repetition time (TR) of 1500 ms an echo time of 57 ms, an in-plane resolution of 4 x 4 mm and a slice thickness of 10 mm with fat suppression and 3 signal averages.
ADC is given by:
ADC = 1/(b200-b800) Ln (S800/S200) where S800 is the signal with a diffusion b-value of 800 s mm-2 (b800) and S200 is the signal with a diffusion b-value of 200 s mm-2 (b200).
Statistical analysis Statistical analysis will be performed by an experienced and trained researcher and statistical advice will be available from Prof. Angela Shore from within the team and Beverly Shields from the NIHR Exeter Clinical Research Facility. Data will be assessed for normality. Depending on the normality of data the differences between the groups will be assessed by either unpaired t-test or Mann-Whitney test.
Sample Size Sixteen participants would need to be recruited per group in order to detect a 1SD difference between groups data with 80% power and an a of 0.05. Twenty participants would be recruited in order to account for drop outs.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Diseased condition | Active comparator | Dietary Supplement: Beetroot juiceCrossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboCrossover design where participants will start in the placebo condition, and after a washout period, move into the other condition. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1. Type 2 Diabetes group; aged between 35 - 75. Able to give informed consent 2. Older adults group; aged between 50 - 75. Not on any regular vasoactive medication and able to give informed consent. 3. Young adults group; aged between18 - 35. Not on any regular vasoactive medication and able to give informed consent.
Key exclusion criteria (11 listed)
- • Antibiotic therapy within the preceding two weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beetroot juiceAlso: James Whites Drinks Ltd140mL concentrated Beetroot juice or placebo juice | Dietary supplement | Diseased condition |
| Placebo | Dietary supplement | Placebo |
Primary outcome
Hepatic perfusion
Time frame: 12 minutes
Each participant will have 2 visits to the MRI facility. On each visit, they will have 4 scans lasting 12 minutes each.
3 secondary outcomes
Plasma glucose concentration
Time frame: 2 minutes
Plasma insulin concentration
Time frame: 2 minutes
Plasma incretin concentration
Time frame: 2 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angela C Shore, PhD study chair
University of Exeter
Anthony I Shepherd, MSc principal investigator
University of Exeter
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Beetroot juice in people with Type 2 Diabetes and Ageing, run by University of Exeter at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hepatic perfusion (time frame: 12 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.